While the hiring freeze bars any federal agencies for filling current open positions, it does allow the “head of any executive department or agency may exempt from the hiring freeze any positions that it deems necessary to meet national security or public safety responsibilities.” It is unclear right now whether this exception applies to the FDA, according to the report.
The FDA’s Office of Generic Drugs is expecting more than 1,500 abbreviated new drug applications, said former FDA official Bob Pollock in a blog post Wednesday. If the freeze applies to the FDA, the timely approval of these new drugs could be affected, according to the report.
“While we are still reviewing the administration’s executive order, patients deserve the best and brightest minds to be able to review the medicines they need,” a spokesman from the industry group Pharmaceutical Research and Manufacturers of America told Regulatory Focus. “The [FDA] is the gold standard, and a stable and sustainable workforce is crucial to [the] agency’s ability to keep pace with scientific advances in biopharmaceutical drug development, while ensuring safe and effective medicines reach patients in a timely manner.”
Along with the hiring freeze, the Trump administration also told federal agencies not to publish any new regulations, rulemakings or new guidance documents, according to the report.
More articles on supply chain:
Tom Price open to CMS negotiating drug prices
6 quotes from Dr. Joseph Gulfo — Trump’s potential pick for FDA commissioner
Johnson & Johnson inks $30B deal with Actelion
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.